|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we have examined HCV genotype 1-, 2-, or 3-specific regulation of lipid metabolism, involving transforming growth factor β (TGF-β)-regulated phospho-Akt (p-Akt) and peroxisome proliferator-activated receptor alpha (PPARα) axes.
|
31243135 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The dysregulation of signaling pathways such as transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), Wnt/β-catenin (WNT), cyclooxygenase-2 (COX-2) and peroxisome proliferator-activated receptor α (PPARα) by HCV core protein is implicated in the development of HCC.
|
30643357 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
2) Expression of PPARA in human liver is reduced in patients with non-alcoholic steatohepatitis or infected with the hepatitis C virus.
|
28077274 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The knockdowns of PPARα and CD36 reversed the LPL-mediated suppression of HCV infection.
|
27665576 |
2017 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We measured peroxisome proliferator-activated receptor α and γ mRNA expression by real-time polymerase chain reaction in liver tissues from 40 subjects infected only with hepatitis C virus, 36 subjects co-infected with hepatitis C virus and human immunodeficiency virus and 11 normal adults.
|
26735218 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARα) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARγ is not, and the effect of hPPARδ is unknown.
|
23891183 |
2013 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In HepG2 cells expressing HCV core protein, the level of ROS increased, the value of NAD(+)/NADH decreased, the activity and expression levels of mRNA and protein of SIRT1 and AMPK decreased, glucose uptake and its regulator gene GLUT2 mRNA levels decreased, glucose production and its regulator genes PEPCK and G6Pase mRNA levels increased, intracellular TG and cholesterol contents and their regulator gene (SREBP-1c, FAS, ACC, HMGR, and HMGS) mRNA levels increased, the glycolytic gene GK and fatty acid oxidation genes PPARα and CPT1A mRNA levels decreased.
|
23510538 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, a significant genotype-independent correlation was found between the expression of APOB, MTTP, PRKAA1 and PPARA, indicating that these networks are functional in HCV-infected liver.
|
20196803 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of genes such as peroxisome proliferator-activated receptor-alpha and the proteasome activator PA28-gamma in HCV-mediated steatosis has been elucidated from studies in genetically altered mice, and the manipulation of these and other pathways may provide an avenue for therapeutic intervention.
|
19187070 |
2009 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results offer the first suggestion that HCV core protein induces spontaneous, persistent, age-dependent and heterogeneous activation of PPARalpha in transgenic mice, which may contribute to the age-dependent and multicentric hepatocarcinogenesis mediated by the core protein.
|
17764115 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, reduced adiponectin levels, loss of adiponectin receptors, and decreased anti-inflammatory peroxisome proliferator-activated receptor alpha in the liver of HCV patients may contribute to reduced fatty acid oxidation, inflammation, and eventually lipotoxicity.
|
18446789 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the contribution of peroxisome proliferator-activated receptor-alpha and -gamma to the pathogenesis of hepatitis C virus associated steatosis is unknown.
|
16393287 |
2006 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis.
|
16297361 |
2005 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results identify hepatic PPARalpha as one mechanism underlying the pathogenesis of HCV infection, and as a new therapeutic target in traditional treatment of HCV-induced liver injury.
|
15685545 |
2005 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
LHGDN |
These results identify hepatic PPARalpha as one mechanism underlying the pathogenesis of HCV infection, and as a new therapeutic target in traditional treatment of HCV-induced liver injury.
|
15685545 |
2005 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPARalpha plays an important role in the pathogenesis of chronic HCV infection, but the impaired function of this nuclear receptor in HCV infection needs further studies.
|
16437683 |
2005 |